Cardiac involvement Is Underdiagnosed in Patients with Biopsy-Proven Systemic AL Amyloidosis

Haoyi Zheng, Amitabha Mazumder, Stuart Katz

Abstract


Background: Clinical recognition of cardiac involvement and cardiac response to therapy is an important element of clinical care in patients with AL amyloidosis. The new criteria including NT-proBNP, troponin, and echocardiography for assessment of cardiac involvement in patients with systemic AL amyloidosis were proposed in 2004, but there are limited data on the utilization of these in clinical practice

Methods: We retrospectively reviewed the clinical data of 28 patients with AL amyloidosis. Clinical diagnosis of cardiac amyloidosis was based on medical record documentation of symptomatic heart failure without other causes. Then we use the criteria from the current NCCN Guidelines to reassess cardiac involvement.

Results: 14 cases (50%) had clinical diagnosis of cardiac amyloidosis at the time of diagnosis and also met the NCCN criteria. An additional 6 cases without clinical diagnosis of cardiac amyloidosis met the NCCN criteria. In total, 20 patients (71.4%) met the NCCN criteria for cardiac involvement. No routine follow-up testing with echocardiography and biomarkers was documented during treatment for any of the patients.


Keywords


AL cardiac amyloidosis; diagnosis; natriuretic peptides; echocardiography; NCCN guidelines

Full Text:

PDF

References


Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.

Palladini G, Dispenzieri A, Gertz MA, et al. New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012. http://dx.doi.org/10.1200/JCO.2011.37.7614

Roberts WC, Waller BF. Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients. The American journal of cardiology 1983;52:137-46.

Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22:3751-7. http://dx.doi.org/10.1200/JCO.2004.03.029

Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2012;19:167-70. http://dx.doi.org/10.3109/13506129.2012.734345

Kumar SK, Gertz MA, Lacy MQ, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clinic proceedings Mayo Clinic 2011;86:12-8. http://dx.doi.org/10.4065/mcp.2010.0480

Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30:989-95. http://dx.doi.org/10.1200/JCO.2011.38.5724

Austin BA, Tang WH, Rodriguez ER, et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovascular imaging 2009;2:1369-77. http://dx.doi.org/10.1016/j.jcmg.2009.08.008

Falk RH. Cardiac amyloidosis: a treatable disease, often overlooked. Circulation 2011;124:1079-85. http://dx.doi.org/10.1161/CIRCULATIONAHA.110.010447

Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.

Palladini G, Dispenzieri A, Gertz MA, et al. New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. Journal of clinical oncology 2012 30:4541–4549 doi: 10.1200/JCO.2011.37.7614

Roberts WC, Waller BF. Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients. The American journal of cardiology 1983;52:137-46.

Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22:3751-7. doi: 10.1200/JCO.2004.03.029

Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-5. doi: 10.1161/01.CIR.0000068314.02595.B2

Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2012;19:167-70. doi: 10.3109/13506129.2012.734345.

Kumar SK, Gertz MA, Lacy MQ, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clinic proceedings Mayo Clinic 2011;86:12-8. doi: 10.4065/mcp.2010.0480.

Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30:989-95. doi: 10.1200/JCO.2011.38.5724

Dispenzieri A, Gertz MA, Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood reviews 2012;26:137-54.

Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107:3854-8. doi: 10.1016/j.blre.2012.03.001.

Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis: recognition, confirmation, prognosis, and therapy. Mayo Clinic proceedings Mayo Clinic 1999;74:490-4.

Austin BA, Tang WH, Rodriguez ER, et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovascular imaging 2009;2:1369-77. doi: 10.1016/j.jcmg.2009.08.008.

Falk RH. Cardiac amyloidosis: a treatable disease, often overlooked. Circulation 2011;124:1079-85. doi: 10.1161/CIRCULATIONAHA.110.010447.

Shewan LG, Coats AJS, Henein M. Requirements for ethical publishing in biomedical journals. International Cardiovascular Forum Journal 2015;2:2 DOI: 10.17987/icfj.v2i1.4.




DOI: https://doi.org/10.17987/icfj.v6i0.172


Copyright (c) 2016 Haoyi Zheng, Amitabha Mazumder, Stuart Katz

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.